RGD Reference Report - The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients.

Authors: Memon, AA  Sorensen, BS  Meldgaard, P  Fokdal, L  Thykjaer, T  Nexo, E 
Citation: Memon AA, etal., Br J Cancer. 2006 Jun 5;94(11):1703-9.
RGD ID: 2298502
Pubmed: PMID:16685269   (View Abstract at PubMed)
PMCID: PMC2361308   (View Article at PubMed Central)
DOI: DOI:10.1038/sj.bjc.6603154   (Journal Full-text)

Increased expression of the epidermal growth factor (EGF) receptors, HER1 and HER2 are related to poor prognosis in most cancers studied. Recently, a high expression of the two remaining receptors of the EGF system, HER3 and HER4 has been related to a favourable prognosis. However, prognostic significance of HER1 and HER2 receptors in bladder cancer is controversial and the effect of the expression of different combinations of these receptors on patient survival is not well understood. Therefore, we examined the mRNA expression of all four EGF receptors with real-time polymerase chain reaction in biopsies from 88 patients with bladder cancer, where the survival was followed for a median of 38.5 months (range 1-117 months). Expression of HER1 and HER2 alone showed no correlation with survival. However, a high expression of HER1 together with high expression of HER3 and HER4 correlated to a better prognosis compared to the high expression of HER1 together with low expression of HER3 and HER4 (P=0.0006). Also, a significantly longer survival was observed in patients expressing high HER2 when coexpressed with high HER3 and HER4, as compared to the survival in patients with tumours expressing high HER2 but low HER3 and HER4 (P=0.0005). Our results suggest that the final outcome of patients with high HER1- and HER2-expressing tumours depends on the expression of HER3 and HER4.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
urinary bladder cancer disease_progressionIEP 2298502; 2298502; 2298502; 2298502 RGD 
urinary bladder cancer disease_progressionISOEGFR (Homo sapiens)2298502; 2298502 RGD 
urinary bladder cancer disease_progressionISOERBB2 (Homo sapiens)2298502; 2298502 RGD 
urinary bladder cancer disease_progressionISOERBB3 (Homo sapiens)2298502; 2298502 RGD 
urinary bladder cancer disease_progressionISOERBB4 (Homo sapiens)2298502; 2298502 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Egfr  (epidermal growth factor receptor)
Erbb2  (erb-b2 receptor tyrosine kinase 2)
Erbb3  (erb-b2 receptor tyrosine kinase 3)
Erbb4  (erb-b2 receptor tyrosine kinase 4)

Genes (Mus musculus)
Egfr  (epidermal growth factor receptor)
Erbb2  (erb-b2 receptor tyrosine kinase 2)
Erbb3  (erb-b2 receptor tyrosine kinase 3)
Erbb4  (erb-b2 receptor tyrosine kinase 4)

Genes (Homo sapiens)
EGFR  (epidermal growth factor receptor)
ERBB2  (erb-b2 receptor tyrosine kinase 2)
ERBB3  (erb-b2 receptor tyrosine kinase 3)
ERBB4  (erb-b2 receptor tyrosine kinase 4)


Additional Information